Physician profile
Leigh E Scharff
NPI 1962756072
$1,598.27
in general payments reported to CMS, 2019-2025
22 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $137 · 2022: $271 · 2023: $411 · 2024: $401 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.40 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $389.35 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $193.23 | 2021-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $94.90 | 2021-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $84.81 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.06 | 2022-2023 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $45.60 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $44.38 | 2023-2024 | Austedo, Austedo Xr |
| Vertex Pharmaceuticals Incorporated | $33.17 | 2025 | |
| Mylan Specialty L.P. | $29.48 | 2024 | Yupelri |
| Sanofi Pasteur INC. | $27.06 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.92 | 2024 | Trintellix |
| Sumitomo Pharma America, INC. | $23.52 | 2025 | Gemtesa |
| Corium, LLC | $21.46 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.21 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.73 | 2023 | Evenity, Prolia |
| Axsome Therapeutics, INC. | $17.57 | 2025 | Auvelity |
| Lundbeck LLC | $17.24 | 2024 | Rexulti |
| Acadia Pharmaceuticals INC | $16.87 | 2024 | Nuplazid |
| Viatris Specialty LLC | $15.24 | 2025 | Yupelri |
| Exact Sciences Corporation | $14.66 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $13.41 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Scharff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.